XML 97 R80.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Details)
 12 Months Ended
Dec. 31, 2024
USD ($)
segment
Dec. 31, 2023
USD ($)
Segment Reporting [Abstract]    
Number of reportable segments | segment 1  
Segment Reporting Information [Line Items]    
Revenue from collaborative arrangements and other contracts, including affiliated entity $ 217,756 $ 832,010
Less:    
Research and development $ 75,620,340 86,676,563
Impairment, Intangible Asset, Statement of Income or Comprehensive Income [Extensible Enumeration] Research and development  
General and administrative $ 36,996,338 47,582,104
Impairment of goodwill 0 10,513,371
Total operating expenses 112,616,678 144,772,038
Interest income 4,766,993 8,133,290
Interest expense (177,833) (1,222,789)
Gain (loss) on investment in affiliated entities (1,166,443) 773,145
Net unrealized gain on available-for-sale equity securities 2,077,182 5,850,626
Other income (expense), net (3,163,711) (4,711,596)
Net loss (107,254,126) (135,117,352)
Reportable Segments    
Segment Reporting Information [Line Items]    
Revenue from collaborative arrangements and other contracts, including affiliated entity 217,756 832,010
Less:    
General and administrative 36,996,338 47,582,104
Impairment of goodwill 0 10,513,371
Total operating expenses 112,616,678 144,772,038
Interest income 4,766,993 8,133,290
Interest expense (177,833) (1,222,789)
Change in fair value of common stock warrant liability 2,808,608 0
Gain (loss) on investment in affiliated entities (1,166,443) 773,145
Net unrealized gain on available-for-sale equity securities 2,077,182 5,850,626
Other income (expense), net (3,163,711) (4,711,596)
Net loss (107,254,126) (135,117,352)
Reportable Segments | INO-3107    
Less:    
Research and development 29,930,344 17,840,728
Reportable Segments | INO-5401 And Other Immuno-oncology    
Less:    
Research and development 6,293,401 11,758,935
Reportable Segments | Other Programs    
Less:    
Research and development (77,955) 18,701,675
Reportable Segments | Engineering And Device-Related    
Less:    
Research and development 19,393,929 8,863,170
Reportable Segments | Stock-Based Compensation    
Less:    
Research and development 2,821,226 4,606,341
Reportable Segments | Other Unallocated Expenses    
Less:    
Research and development $ 17,259,395 24,905,714
Impairment   $ 2,000,000